Loading…
Product type
Ibrutinib is a targeted therapy used primarily in the treatment of certain types of blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is a small molecule inhibitor that works by blocking a specific protein called Bruton's tyrosine kinase (BTK), which plays a crucial role in the survival and proliferation of malignant B cells. Ibrutinib is typically produced through complex chemical synthesis processes to ensure high purity and potency.
| Chemical formula | C19H20N6O2 |
| Molecular weight | 440.41 g/mol |
| Purity | ≥ 98% by HPLC |
| Form | Powder |
| Storage conditions | Store at 20°C to 25°C |
When selecting Ibrutinib as an active pharmaceutical ingredient, buyers should consider the required purity levels and the specific formulation needs for their applications. It is essential to specify any necessary certifications, such as Good Manufacturing Practice (GMP) compliance, and to communicate the desired quantities for production. Additionally, understanding the stability and storage requirements can help ensure optimal use in formulations.
Get quotes for Ibrutinib
Tell us your requirement — quantity, specs and timeline — and our team sources verified manufacturers and brings you the best quote.
Ibrutinib is used primarily to treat certain types of blood cancers, including CLL and MCL.
Ibrutinib is typically administered orally in capsule form.
Common side effects include diarrhea, fatigue, and increased risk of infections.
No, Ibrutinib is a targeted therapy and not a traditional chemotherapy drug.
Consider purity, certification, and the specific formulation requirements.
Yes, Ibrutinib is often used in combination with other cancer therapies.